
Reports Q3 revenue $559K, consensus $244.3K. The company states: “Since our August update, we have continued to advance our dialogue with the FDA. Our FDA reviewers have been engaged, and
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IMDX | Insight Molecular Diagnostics | 1.86 | -4.57 | -71.08% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.86 | -71.08% |

Reports Q3 revenue $559K, consensus $244.3K. The company states: “Since our August update, we have continued to advance our dialogue with the FDA. Our FDA reviewers have been engaged, and

Insight Molecular Diagnostics (IMDX) announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants

Insight Molecular Diagnostics Inc. (IMDX) is scheduled to report 3rd quarter earnings on 11/16/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Insight Molecular Diagnostics Inc. to

Insight Molecular Diagnostics ( ($IMDX) ) has issued an announcement. Insight Molecular Diagnostics Inc. operates in the molecular diagnostics industry, focusing on blood-based tests that analyze cell-free DNA to monitor

Lucid Capital initiated coverage of Insight Molecular Diagnostics (IMDX) with a Buy rating and $8 price target The company is seeking to compete directly against the send-out central lab model,

Insight Molecular Diagnostics Inc. (($IMDX)) has held its Q2 earnings call. Read on for the main highlights of the call. Insight Molecular Diagnostics Inc.’s latest earnings call struck an upbeat

Michael Matson, an analyst from Needham, reiterated the Buy rating on Insight Molecular Diagnostics. The associated price target remains the same with $9.00. Michael Matson has given his Buy rating

In a report released today, Michael Matson from Needham assigned a Buy rating on Insight Molecular Diagnostics, with a price target of $9.00. Michael Matson has given his Buy rating

Insight Molecular Diagnostics ( ($IMDX) ) has shared an update. In late July 2026, Insight Molecular Diagnostics reported that the FDA had completed a key phase of its substantive review

Reports Q2 revenue $239,000, consensus $437,500. The company said, “Our Q2 2026 outgoing cash flow from operations (net cash used in operating activities) of $9.3 million, combined with capital expenditures
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $70.03M | ― | ― | 0.07 | -1.41 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.